{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:36:38Z","timestamp":1769106998109,"version":"3.49.0"},"reference-count":20,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1536\/ihj.15-103","type":"journal-article","created":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T18:05:04Z","timestamp":1441908304000},"page":"564-567","source":"Crossref","is-referenced-by-count":10,"title":["An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension"],"prefix":"10.1536","volume":"56","author":[{"given":"Daisuke","family":"Nitta","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyoko","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Organ Transplantation, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Inaba","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Packer M, Fowler MB, Roecker EB, <i>et al<\/i>. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.","DOI":"10.1161\/01.CIR.0000035653.72855.BF"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. Adv Ther 2014; 31: 440-50.","DOI":"10.1007\/s12325-014-0116-x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagai R, Kinugawa K, Inoue H, <i>et al<\/i>. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultrashort-acting beta1-selective blocker landiolol with digoxin (J-Land Study). Circ J 2013; 77: 908-16.","DOI":"10.1253\/circj.CJ-12-1618"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kinugawa K, Nagai R, Inoue H, <i>et al<\/i>. Impacts of patient characteristics on the effectiveness of landiolol in AF\/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther 2014; 31: 426-39.","DOI":"10.1007\/s12325-014-0111-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Van Gelder IC, Groenveld HF, Crijns HJ, <i>et al<\/i>. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-73.","DOI":"10.1056\/NEJMoa1001337"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30: 1039-45.","DOI":"10.1016\/S0735-1097(97)00254-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D. (Review)","DOI":"10.1016\/S0002-9149(02)03373-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wang TJ, Larson MG, Levy D, <i>et al<\/i>. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-5.","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009; 11: 676-83.","DOI":"10.1093\/eurjhf\/hfp085"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wyse DG, Waldo AL, DiMarco JP, <i>et al<\/i>. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.","DOI":"10.1056\/NEJMoa021328"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sairaku A, Yoshida Y, Hirayama H, Nakano Y, Kihara Y. Impact of pulmonary vein isolation on fractionated atrial potentials and ganglionated plexi in patients with persistent atrial fibrillation. Int Heart J 2014; 55: 494-8.","DOI":"10.1536\/ihj.14-147"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fuster V, Ryden LE, Cannom DS, <i>et al<\/i>. 2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-98.","DOI":"10.1016\/j.jacc.2010.09.013"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients \u2265 65 years of age with versus without heart failure. Am J Cardiol 2014; 114: 401-6.","DOI":"10.1016\/j.amjcard.2014.05.013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sasaki N, Watanabe I, Kogawa R, <i>et al<\/i>. Effects of intravenous amiodarone and ibutilide on action potential duration and atrial conduction kinetics in patients with persistent atrial fibrillation. Int Heart J 2014; 55: 244-8.","DOI":"10.1536\/ihj.13-254"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983; 34: 427-34.","DOI":"10.1038\/clpt.1983.193"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Iguchi S, Iwamura H, Nishizaki M, <i>et al<\/i>. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo) 1992; 40: 1462-9.","DOI":"10.1248\/cpb.40.1462"},{"key":"19","unstructured":"19. Sugiura S, Hidaka K, Seki S, Tsuchida H. Comparative study of two beta adrenergic antagonists on hemodynamics at the endotracheal intubation. Annual meeting of the American Society of Anesthesiologists; 2007: A309. Available at : http:\/\/www.asaabstracts.com\/strands\/asaabstracts\/abstract.htm;jsessionid=7AB1B76F7CEE0435C8B2198FF104CA4F?year=2007&amp;index=4&amp;absnum=1298 Accessed Jun 10, 2015."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Stevenson LW, Pagani FD, Young JB, <i>et al<\/i>. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28: 535-41.","DOI":"10.1016\/j.healun.2009.02.015"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/56\/5\/56_15-103\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T15:16:42Z","timestamp":1498231002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/56\/5\/56_15-103\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.15-103","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}